Gene Therapy may be a ways out from mainstream medicine but some interesting results are out there...look at work in certain types of blindness.
Timelines aside....they have the market caps of multiple stem companies combined. They also have the eye of BP and most still have low stock floats .
Cytori will have north of 200 million shares soon....I also don't expect the buybacks DOV does...especially in the timeline he does. Profits will need to be used to expand indications.